Maven Securities LTD Acquires New Shares in MDxHealth SA (NASDAQ:MDXH)

Maven Securities LTD bought a new position in MDxHealth SA (NASDAQ:MDXH) during the 3rd quarter, Holdings Channel.com reports. The institutional investor bought 100,148 shares of the company’s stock, valued at approximately $208,000.

Other hedge funds also recently added to or reduced their stakes in the company. MVM Partners LLC grew its position in shares of MDxHealth by 3.3% during the third quarter. MVM Partners LLC now owns 4,700,457 shares of the company’s stock worth $9,706,000 after acquiring an additional 150,000 shares during the last quarter. Perkins Capital Management Inc. boosted its stake in MDxHealth by 70.7% during the 3rd quarter. Perkins Capital Management Inc. now owns 747,375 shares of the company’s stock valued at $1,555,000 after purchasing an additional 309,500 shares during the period. Finally, OneDigital Investment Advisors LLC grew its position in MDxHealth by 15.3% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company’s stock worth $120,000 after purchasing an additional 7,656 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Lake Street Capital started coverage on MDxHealth in a report on Thursday, October 31st. They set a “buy” rating and a $7.00 price target on the stock. Piper Sandler reduced their price target on MDxHealth from $8.00 to $6.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th.

MDxHealth Price Performance

Shares of NASDAQ:MDXH opened at $2.01 on Friday. The company has a 50 day moving average of $1.96 and a 200-day moving average of $2.46. The company has a quick ratio of 1.45, a current ratio of 1.54 and a debt-to-equity ratio of 3.14. MDxHealth SA has a twelve month low of $1.55 and a twelve month high of $4.64.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.